Blog
RSS FeedPosted by Michael Wonder on 06 Feb 2018
NICE restricts NHS use of Roche’s IPF drug Esbriet
6 February 2018 - Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the ...
Posted by Michael Wonder on 05 Feb 2018
Announcing the passing of Professor Alan Maynard
5 February 2018 - The University of York is deeply saddened to announce that Alan Maynard, Emeritus Professor of Health Economics ...
Posted by Michael Wonder on 01 Feb 2018
NHS England takes charge on market access
1 February 2018 - Today sees patients gain full NHS access to breast cancer drug Perjeta, a full six years ...
Posted by Michael Wonder on 01 Feb 2018
Final NHS nod for Janssen’s Imbruvica
1 February 2018 - Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell ...
Posted by Michael Wonder on 01 Feb 2018
NICE, the NHS, and cancer drugs
31 January 2018 - Drug costs are an issue in virtually every country and particularly in the United States. In ...
Posted by Michael Wonder on 31 Jan 2018
`Life-changing´ breast cancer drug can be routinely used in NHS, says NICE
31 January 2018 - A “life-changing” drug for breast cancer patients has been given the final go-ahead for routine NHS ...
Posted by Michael Wonder on 31 Jan 2018
CDF to save NHS £140m over five years
31 January 2018 - At least £140 million is expected to be released into the NHS over the next five ...
Posted by Michael Wonder on 29 Jan 2018
Doctors are cleared to prescribe cheaper drug for wet AMD
24 January 2018 - Doctors who prescribe bevacizumab (Avastin) for age related macular degeneration (AMD) will “not raise fitness to ...
Posted by Michael Wonder on 28 Jan 2018
Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments
19 January 2018 - Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. ...
Posted by Michael Wonder on 24 Jan 2018
Director at NICE leaves after 17 years
24 January 2018 - Professor Carole Longson, director of the Health Technology Evaluation Centre, is to leave NICE to move on ...
Posted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 23 Jan 2018
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
23 January 2018 - Cost regulators for NHS funded therapies in England and Wales have issued updated guidelines for the ...
Posted by Michael Wonder on 22 Jan 2018
Biogen ‘optimistic’ for NHS access to Spinraza
22 January 2018 - Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder ...
Posted by Michael Wonder on 17 Jan 2018
Pfizer asked to submit CDF proposal for Xalkori
17 January 2018 - Pfizer’s Xalkori has been turned away by NICE to treat ROS1-positive advanced non-small cell lung cancer. ...